title: Weekly low-dose doxorubicin with or without high-dose medroxyprogesterone acetate as secondary treatment in metastatic breast cancer--a randomized trial.
authors.affiliation: Department of Radiotherapy and Oncology, University of Helsinki, Finland.
authors.forename: I
authors.initials: I
authors.lastname: Elomaa
authors.forename: C
authors.initials: C
authors.lastname: Blomqvist
authors.forename: P
authors.initials: P
authors.lastname: Rissanen
authors.forename: M
authors.initials: M
authors.lastname: Mäntylä
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011897:Random Allocation
chemical_list: D004317:Doxorubicin; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone